Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines.
Most candidate human immunodeficiency virus (HIV)-1 vaccines induce antibodies that neutralize T cell line-adapted HIV-1 strains. Until recently, however, no neutralizing activity against primary HIV-1 isolates had been demonstrated in sera from human vaccinees. Since most candidate HIV-1 vaccines have been constructed from T cell line-adapted syncytium-inducing (SI) strains, experiments were done to test whether sera from recipients of SI-based vaccines could preferentially neutralize SI primary HIV-1 isolates. Various neutralization assays were performed with sera from volunteers receiving ALVACgp160MN and/or rgp120SF2. Neutralizing activity was detected against 4 of 8 SI primary isolates but against none of 5 non-SI primary isolates. The data suggest that, for the induction of neutralizing antibodies to a broad array of HIV-1 primary isolates, a polyvalent vaccine will be needed containing representatives of more than a single category of viruses.
Department of Veterans Affairs Medical Center, New York, USA. ZOLLAS01@MCRCR6.med.nyu.edu
S
S
Zolla-Pazner
S
S
Xu
S
S
Burda
A M
AM
Duliege
J L
JL
Excler
M L
ML
Clements-Mann
D016915:AIDS Vaccines / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D000940:Antigenic Variation; D005260:Female; D015726:Giant Cells / Q000276:immunology / Q000821:virology; D015483:HIV Antibodies / Q000096:biosynthesis; D019302:HIV Envelope Protein gp160 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged
D016915:AIDS Vaccines; D015483:HIV Antibodies; D019302:HIV Envelope Protein gp160